Skyhawk's Huntington's Drug Shows Early Efficacy, Expands Phase 2/3 Trial
Event summary
- Skyhawk's SKY-0515 showed mean improvement of +0.64 points in cUHDRS at nine months, vs. expected worsening of -0.73 points in Huntington's patients.
- Phase 2/3 FALCON-HD trial expanded worldwide, with over 90 patients dosed.
- SKY-0515 achieved 62% reduction in mHTT protein and 26% reduction in PMS1 mRNA at 9mg dose.
- Company plans to initiate additional clinical programs for rare neurological diseases by end of 2027.
The big picture
Skyhawk's positive interim data positions SKY-0515 as a potential best-in-class therapy for Huntington's disease, a market with no approved disease-modifying treatments. The global expansion of the Phase 2/3 trial reflects growing confidence in the drug's clinical profile. Skyhawk's platform approach could position it as a key player in developing therapies for other rare neurological diseases with high unmet need.
What we're watching
- Clinical Validation
- Whether the open-label Phase 1 results will be confirmed in the placebo-controlled FALCON-HD trial.
- Pipeline Expansion
- The pace at which Skyhawk can advance additional small molecule programs into the clinic.
- Competitive Positioning
- How SKY-0515's dual mechanism of action will differentiate it in the Huntington's disease treatment landscape.
Our editorial coverage:
Related topics